EDG004 Treatment of Adult Patients With Generalized Anxiety Disorder (GAD)
NCT ID: NCT02305797
Last Updated: 2018-09-26
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
495 participants
INTERVENTIONAL
2015-01-31
2016-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Proof of Concept in Patients With Generalized Anxiety Disorder (GAD)AZD7325
NCT00807937
Experimental Medication For the Treatment of Generalized Anxiety Disorder
NCT00097708
A Study to Assess the Efficacy and Safety of CD-008-0045 in Patients With Generalized Anxiety Disorder
NCT04598867
A Long-Term Study Continuing on From Study 04-001-01 of an Experimental Medication in Adults With Anxiety Disorder
NCT00106860
AZD7325 Proof of Concept in Patients With Generalized Anxiety Disorder (GAD)
NCT00808249
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
EDG004
EDG004 - Extended release lorazepam capsules
Extended-release lorazepam
Extended-release lorazepam capsules
Placebo
Placebo
Placebo
Placebo capsules
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Extended-release lorazepam
Extended-release lorazepam capsules
Placebo
Placebo capsules
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Diagnosed with GAD and
* No other psychiatric conditions, and are otherwise medically healthy.
Exclusion Criteria
18 Years
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Edgemont Pharmaceuticals, LLC
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Multiple Investigational Sites
Multiple Locations, California, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
EDG004-003
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.